Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study to Compare the Natural History of Ataxia Telangiectasia (AT) in Children to Healthy Comparators (INSPIRE AT)

18. november 2026 opdateret af: Insmed Incorporated

INSPIRE AT: Longitudinal Study Comparing the Natural History of Ataxia Telangiectasia in Children to Healthy Comparators

The primary objective of this study is to assess the natural history of AT symptoms and disease progression over time in children aged 1 to 10 years old diagnosed with classic AT.

Studieoversigt

Status

Rekruttering

Betingelser

Undersøgelsestype

Observationel

Tilmelding (Anslået)

69

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

      • Nottingham, Det Forenede Kongerige, NG7 2UH
        • Rekruttering
        • GBR001
    • California
      • Los Angeles, California, Forenede Stater, 90095
        • Ikke rekrutterer endnu
        • USA004
    • Maryland
      • Baltimore, Maryland, Forenede Stater, 21287-0005
        • Rekruttering
        • USA002
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02114
        • Rekruttering
        • USA001
    • Texas
      • Houston, Texas, Forenede Stater, 77030-3008
        • Rekruttering
        • USA003

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

1 år til 10 år (Barn)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Participants who meet all the inclusion criteria and none of the exclusion criteria will be eligible for inclusion in their respective cohort as appropriate.

Beskrivelse

Inclusion Criteria for the AT Cohort:

  • Diagnosis of classic AT based on investigator's assessment of clinical presentation and genotyping.
  • If three years to 10 years (<11 years) old, the primary caregiver has self-reported to the site that the participant with AT can walk approximately 33 feet (10 meters) without support from a helper, and without the use of a walking aid.
  • Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver informed consent form.

Inclusion Criteria for the Healthy Comparator Cohort:

  • Provision of a valid study participant assent form, as applicable, together with a correctly signed and dated primary caregiver consent form.

Exclusion Criteria for the AT Cohort:

  • Participation in a clinical trial of a candidate therapeutic for AT, with last administration of a candidate therapeutic within 30 days or five half-lives (whichever is longer) preceding study baseline (start of data collection). For clarity, ongoing clinical trial participation that does not involve a therapeutic drug is acceptable. An exception to this exclusion is that up to approximately 20 participants receiving levacetylleucine (marketed as AQNEURSA®) in investigational trials, expanded access programs, or as a licensed drug are eligible.
  • Previous treatment with a chemotherapeutic agent for cancer.
  • Diagnosis of a condition other than AT that, in the opinion of the investigator, would compromise AT symptom measurement or current study participation.

Exclusion Criteria for the Healthy Comparator Cohort:

  • Diagnosis of any form of AT.
  • Previous treatment with a chemotherapeutic agent for cancer.
  • Diagnosis of a condition that, in the opinion of the investigator, would compromise the measurement of movement by wearable devices to serve as healthy comparators to AT participants.

Note: Other protocol-defined inclusion/exclusion criteria may apply.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Observationsmodeller: CASE_CONTROL
  • Tidsperspektiver: PROSPECTIVE

Kohorter og interventioner

Gruppe / kohorte
AT Cohort

Participants with confirmed AT at screening visit will be enrolled and followed for 24 months.

Healthy Comparator Cohort

Participants without diagnosis of AT at screening visit will be enrolled and followed for 24 months.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
AT Cohort: Change From Baseline in AT Neurological Examination Scale Toolkit (A-TNEST) Score
Tidsramme: Baseline up to Month 24
Baseline up to Month 24
AT Cohort: Change From Baseline in International Cooperative Ataxia Rating Scale (ICARS) Score
Tidsramme: Baseline up to Month 24
Baseline up to Month 24

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change From Baseline in Height
Tidsramme: Baseline up to Month 24
Baseline up to Month 24
Change From Baseline in Weight
Tidsramme: Baseline up to Month 24
Baseline up to Month 24
Percentage of Participants Achieving Pre-defined Developmental Goals as Assessed by Denver Developmental Screening Test (DDST-II)
Tidsramme: Up to Month 24
Up to Month 24
AT Cohort: Change From Baseline in Pediatric Quality of Life Inventory (Peds QL) Score Measured by the Pediatric Quality of Life Inventory
Tidsramme: Baseline up to Month 24
Baseline up to Month 24
Change From Baseline in Motor Activity Assessed by Wearable Device
Tidsramme: Baseline up to Month 24

A wearable accelerometer will capture participant's movements during their everyday activities at home. These data will be processed using specific algorithms to generate measurements that include total sedentary time and time spent in light, moderate and vigorous activity.

Baseline up to Month 24
Change From Baseline in Arm Function Assessed by Hevelius Test
Tidsramme: Baseline up to Month 24
Baseline up to Month 24

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Efterforskere

  • Studieleder: Study Director, Insmed Incorporated

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

30. juni 2026

Primær færdiggørelse (Anslået)

30. maj 2029

Studieafslutning (Anslået)

30. maj 2029

Datoer for studieregistrering

Først indsendt

30. oktober 2026

Først indsendt, der opfyldte QC-kriterier

18. november 2026

Først opslået (Faktiske)

19. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

19. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

18. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • INS NHS AT001

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .